Haemoglobinopathies - Global Market Outlook (2016-2022)
According to Stratistics MRC, the Global Hemoglobinopathie market is accounted for $4.6 billion in 2015 and is expected to reach $8.99 billion by 2022 growing at a CAGR of 10.0% from 2015 to 2022. Increasing incidences of hemoglobin disorders with strong product portfolio for sickle cell anemia such as HQK-1001 and Luspatercept, government’s awareness programs and advanced diagnostics and therapeutics will fuel the market growth. Research & development and growth across developed and developing economies will provide opportunity for the market growth. Instrumentation cost and expertise required for LC MS/MS, molecular identification of the alpha and beta chain mutations are some of the factors that impede the market growth.
Hydroxyurea was one of the dominating segments followed by Thalassemia and is estimated to grow at lucrative growth rate. Blood tests and pre-implant genetic testing is anticipated to grow further during forecast period. The market for blood transfusion was the largest with revenues in therapeutic segment. North America dominated the overall market. Africa, Asia Pacific and the Mediterranean regions are projected to show profitable growth.
Some of the key players in global Hemoglobinopathie market are Gamida Cell,Alnylam Pharmaceuticals, Biogen Idec, Genetix Pharmaceuticals, Global Blood Therapeutics Inc., Pfizer Inc., Mast Therapeutics, Emmaus Life Sciences, Inc., Prolong Pharmaceuticals, Celgene Corporation, HemaQuest Pharmaceuticals, Sangamo BioSciences Inc, Cancer Therapeutics CRC Pty Ltd, Datar Genetics Limited, Optinova Ab, Anthera Pharmaceuticals and AcceleronPharma.
Disorders Covered:
Hydroxyurea was one of the dominating segments followed by Thalassemia and is estimated to grow at lucrative growth rate. Blood tests and pre-implant genetic testing is anticipated to grow further during forecast period. The market for blood transfusion was the largest with revenues in therapeutic segment. North America dominated the overall market. Africa, Asia Pacific and the Mediterranean regions are projected to show profitable growth.
Some of the key players in global Hemoglobinopathie market are Gamida Cell,Alnylam Pharmaceuticals, Biogen Idec, Genetix Pharmaceuticals, Global Blood Therapeutics Inc., Pfizer Inc., Mast Therapeutics, Emmaus Life Sciences, Inc., Prolong Pharmaceuticals, Celgene Corporation, HemaQuest Pharmaceuticals, Sangamo BioSciences Inc, Cancer Therapeutics CRC Pty Ltd, Datar Genetics Limited, Optinova Ab, Anthera Pharmaceuticals and AcceleronPharma.
Disorders Covered:
- Sickle Cell Disease
- Haemoglobin variants diseases
- Haemoglobin C disease
- Haemoglobin S-C disease
- Thalassemia
- NiCord
- ZFP Transcription Factors
- ALN-TMP
- Drug Targeting PRMT5
- Drug Targeting Protein Arginine Methyltransferase 5
- Genetic Testing
- Blood Testing
- Pre-implantation Genetic Diagnosis
- Prenatal Genetic Testing
- Haemoglobin Electrophoresis
- Iron Chelation Therapy
- Blood Transfusion
- Hydroxyurea
- Bone Marrow Transplant
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- Italy
- UK
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- Rest of Asia Pacific
- Rest of the World
- Middle East
- Brazil
- Argentina
- South Africa
- Egypt
- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
1 EXECUTIVE SUMMARY
2 PREFACE
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 MARKET TREND ANALYSIS
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.7 Emerging markets
4 PORTERS FIVE FORCE ANALYSIS
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 GLOBAL HAEMOGLOBINOPATHIES MARKET, BY DISORDER
5.1 Introduction
5.2 Sickle Cell Disease
5.3 Haemoglobin variants diseases
5.3.1 Haemoglobin C disease
5.3.2 Haemoglobin S-C disease
5.4 Thalassemia
5.4.1 Alpha Thalassemia
5.4.2 Beta Thalassemia
6 GLOBAL HAEMOGLOBINOPATHIES MARKET, BY DRUG
6.1 Introduction
6.2 NiCord
6.3 ZFP Transcription Factors
6.4 ALN-TMP
6.5 Drug Targeting PRMT5
6.6 Drug Targeting Protein Arginine Methyltransferase
7 GLOBAL HAEMOGLOBINOPATHIES MARKET, BY DIAGNOSIS
7.1 Introduction
7.2 Genetic Testing
7.3 Blood Testing
7.4 Pre-implantation Genetic Diagnosis
7.5 Prenatal Genetic Testing
7.6 Haemoglobin Electrophoresis
8 GLOBAL HAEMOGLOBINOPATHIES MARKET, BY THERAPY
8.1 Introduction
8.2 Iron Chelation Therapy
8.3 Blood Transfusion
8.4 Hydroxyurea
8.5 Bone Marrow Transplant
9 GLOBAL HAEMOGLOBINOPATHIES MARKET, BY GEOGRAPHY
9.1 North America
9.1.1 US
9.1.2 Canada
9.1.3 Mexico
9.2 Europe
9.2.1 Germany
9.2.2 France
9.2.3 Italy
9.2.4 UK
9.2.5 Spain
9.2.9 Rest of Europe
9.3 Asia Pacific
9.3.1 Japan
9.3.2 China
9.3.3 India
9.3.4 Australia
9.3.5 New Zealand
9.3.9 Rest of Asia Pacific
9.4 Rest of the World
9.4.1 Middle East
9.4.2 Brazil
9.4.3 Argentina
9.4.4 South Africa
9.4.5 Egypt
10 KEY DEVELOPMENTS
10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies
11 COMPANY PROFILING
11.1 Gamida Cell
11.2 Alnylam Pharmaceuticals
11.3 Biogen Idec
11.4 Genetix Pharmaceuticals
11.5 Global Blood Therapeutics Inc.
11.6 Pfizer Inc.
11.7 Mast Therapeutics
11.8 Emmaus Life Sciences, Inc.
11.9 Prolong Pharmaceuticals
11.10 Celgene Corporation
11.11 HemaQuest Pharmaceuticals
11.12 Sangamo BioSciences Inc
11.13 Cancer Therapeutics CRC Pty Ltd
11.14 Datar Genetics Limited
11.15 Optinova Ab
11.16 Anthera Pharmaceuticals
11.17 AcceleronPharma
2 PREFACE
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 MARKET TREND ANALYSIS
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.7 Emerging markets
4 PORTERS FIVE FORCE ANALYSIS
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 GLOBAL HAEMOGLOBINOPATHIES MARKET, BY DISORDER
5.1 Introduction
5.2 Sickle Cell Disease
5.3 Haemoglobin variants diseases
5.3.1 Haemoglobin C disease
5.3.2 Haemoglobin S-C disease
5.4 Thalassemia
5.4.1 Alpha Thalassemia
5.4.2 Beta Thalassemia
6 GLOBAL HAEMOGLOBINOPATHIES MARKET, BY DRUG
6.1 Introduction
6.2 NiCord
6.3 ZFP Transcription Factors
6.4 ALN-TMP
6.5 Drug Targeting PRMT5
6.6 Drug Targeting Protein Arginine Methyltransferase
7 GLOBAL HAEMOGLOBINOPATHIES MARKET, BY DIAGNOSIS
7.1 Introduction
7.2 Genetic Testing
7.3 Blood Testing
7.4 Pre-implantation Genetic Diagnosis
7.5 Prenatal Genetic Testing
7.6 Haemoglobin Electrophoresis
8 GLOBAL HAEMOGLOBINOPATHIES MARKET, BY THERAPY
8.1 Introduction
8.2 Iron Chelation Therapy
8.3 Blood Transfusion
8.4 Hydroxyurea
8.5 Bone Marrow Transplant
9 GLOBAL HAEMOGLOBINOPATHIES MARKET, BY GEOGRAPHY
9.1 North America
9.1.1 US
9.1.2 Canada
9.1.3 Mexico
9.2 Europe
9.2.1 Germany
9.2.2 France
9.2.3 Italy
9.2.4 UK
9.2.5 Spain
9.2.9 Rest of Europe
9.3 Asia Pacific
9.3.1 Japan
9.3.2 China
9.3.3 India
9.3.4 Australia
9.3.5 New Zealand
9.3.9 Rest of Asia Pacific
9.4 Rest of the World
9.4.1 Middle East
9.4.2 Brazil
9.4.3 Argentina
9.4.4 South Africa
9.4.5 Egypt
10 KEY DEVELOPMENTS
10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies
11 COMPANY PROFILING
11.1 Gamida Cell
11.2 Alnylam Pharmaceuticals
11.3 Biogen Idec
11.4 Genetix Pharmaceuticals
11.5 Global Blood Therapeutics Inc.
11.6 Pfizer Inc.
11.7 Mast Therapeutics
11.8 Emmaus Life Sciences, Inc.
11.9 Prolong Pharmaceuticals
11.10 Celgene Corporation
11.11 HemaQuest Pharmaceuticals
11.12 Sangamo BioSciences Inc
11.13 Cancer Therapeutics CRC Pty Ltd
11.14 Datar Genetics Limited
11.15 Optinova Ab
11.16 Anthera Pharmaceuticals
11.17 AcceleronPharma
LIST OF TABLES
1 Global Haemoglobinopathies Market Analysis, by Region, (2013-2022) ($MN)
2 Global Haemoglobinopathies Market Analysis, by Disorder, (2013-2022) ($MN)
3 Global Haemoglobinopathies Market Analysis, by Sickle Cell Disease, (2013-2022) ($MN)
4 Global Haemoglobinopathies Market Analysis, by Haemoglobin variants diseases, (2013-2022) ($MN)
5 Global Haemoglobinopathies Market Analysis, by Haemoglobin C disease, (2013-2022) ($MN)
6 Global Haemoglobinopathies Market Analysis, by Haemoglobin S-C disease, (2013-2022) ($MN)
7 Global Haemoglobinopathies Market Analysis, by Thalassemia, (2013-2022) ($MN)
8 Global Haemoglobinopathies Market Analysis, by Alpha Thalassemia, (2013-2022) ($MN)
9 Global Haemoglobinopathies Market Analysis, by Beta Thalassemia, (2013-2022) ($MN)
10 Global Haemoglobinopathies Market Analysis, by Drug, (2013-2022) ($MN)
11 Global Haemoglobinopathies Market Analysis, by NiCord, (2013-2022) ($MN)
12 Global Haemoglobinopathies Market Analysis, by ZFP Transcription Factors, (2013-2022) ($MN)
13 Global Haemoglobinopathies Market Analysis, by ALN-TMP, (2013-2022) ($MN)
14 Global Haemoglobinopathies Market Analysis, by Drug Targeting PRMT5, (2013-2022) ($MN)
15 Global Haemoglobinopathies Market Analysis, by Drug Targeting Protein Arginine Methyltransferase 5, (2013-2022) ($MN)
16 Global Haemoglobinopathies Market Analysis, by Diagnosis, (2013-2022) ($MN)
17 Global Haemoglobinopathies Market Analysis, by Genetic Testing, (2013-2022) ($MN)
18 Global Haemoglobinopathies Market Analysis, by Blood Testing, (2013-2022) ($MN)
19 Global Haemoglobinopathies Market Analysis, by Pre-implantation Genetic Diagnosis, (2013-2022) ($MN)
20 Global Haemoglobinopathies Market Analysis, by Prenatal Genetic Testing, (2013-2022) ($MN)
21 Global Haemoglobinopathies Market Analysis, by Haemoglobin Electrophoresis, (2013-2022) ($MN)
22 Global Haemoglobinopathies Market Analysis, by Therapy, (2013-2022) ($MN)
23 Global Haemoglobinopathies Market Analysis, by Iron Chelation Therapy, (2013-2022) ($MN)
24 Global Haemoglobinopathies Market Analysis, by Blood Transfusion, (2013-2022) ($MN)
25 Global Haemoglobinopathies Market Analysis, by Hydroxyurea, (2013-2022) ($MN)
26 Global Haemoglobinopathies Market Analysis, by Bone Marrow Transplant, (2013-2022) ($MN)
27 North America Haemoglobinopathies Market Analysis, by Country, (2013-2022) ($MN)
28 North America Haemoglobinopathies Market Analysis, by Disorder, (2013-2022) ($MN)
29 North America Haemoglobinopathies Market Analysis, by Sickle Cell Disease, (2013-2022) ($MN)
30 North America Haemoglobinopathies Market Analysis, by Haemoglobin variants diseases, (2013-2022) ($MN)
31 North America Haemoglobinopathies Market Analysis, by Haemoglobin C disease, (2013-2022) ($MN)
32 North America Haemoglobinopathies Market Analysis, by Haemoglobin S-C disease, (2013-2022) ($MN)
33 North America Haemoglobinopathies Market Analysis, by Thalassemia, (2013-2022) ($MN)
34 North America Haemoglobinopathies Market Analysis, by Alpha Thalassemia, (2013-2022) ($MN)
35 North America Haemoglobinopathies Market Analysis, by Beta Thalassemia, (2013-2022) ($MN)
36 North America Haemoglobinopathies Market Analysis, by Drug, (2013-2022) ($MN)
37 North America Haemoglobinopathies Market Analysis, by NiCord, (2013-2022) ($MN)
38 North America Haemoglobinopathies Market Analysis, by ZFP Transcription Factors, (2013-2022) ($MN)
39 North America Haemoglobinopathies Market Analysis, by ALN-TMP, (2013-2022) ($MN)
40 North America Haemoglobinopathies Market Analysis, by Drug Targeting PRMT5, (2013-2022) ($MN)
41 North America Haemoglobinopathies Market Analysis, by Drug Targeting Protein Arginine Methyltransferase 5, (2013-2022) ($MN)
42 North America Haemoglobinopathies Market Analysis, by Diagnosis, (2013-2022) ($MN)
43 North America Haemoglobinopathies Market Analysis, by Genetic Testing, (2013-2022) ($MN)
44 North America Haemoglobinopathies Market Analysis, by Blood Testing, (2013-2022) ($MN)
45 North America Haemoglobinopathies Market Analysis, by Pre-implantation Genetic Diagnosis, (2013-2022) ($MN)
46 North America Haemoglobinopathies Market Analysis, by Prenatal Genetic Testing, (2013-2022) ($MN)
47 North America Haemoglobinopathies Market Analysis, by Haemoglobin Electrophoresis, (2013-2022) ($MN)
48 North America Haemoglobinopathies Market Analysis, by Therapy, (2013-2022) ($MN)
49 North America Haemoglobinopathies Market Analysis, by Iron Chelation Therapy, (2013-2022) ($MN)
50 North America Haemoglobinopathies Market Analysis, by Blood Transfusion, (2013-2022) ($MN)
51 North America Haemoglobinopathies Market Analysis, by Hydroxyurea, (2013-2022) ($MN)
52 North America Haemoglobinopathies Market Analysis, by Bone Marrow Transplant, (2013-2022) ($MN)
53 Europe Haemoglobinopathies Market Analysis, by Country, (2013-2022) ($MN)
54 Europe Haemoglobinopathies Market Analysis, by Disorder, (2013-2022) ($MN)
55 Europe Haemoglobinopathies Market Analysis, by Sickle Cell Disease, (2013-2022) ($MN)
56 Europe Haemoglobinopathies Market Analysis, by Haemoglobin variants diseases, (2013-2022) ($MN)
57 Europe Haemoglobinopathies Market Analysis, by Haemoglobin C disease, (2013-2022) ($MN)
58 Europe Haemoglobinopathies Market Analysis, by Haemoglobin S-C disease, (2013-2022) ($MN)
59 Europe Haemoglobinopathies Market Analysis, by Thalassemia, (2013-2022) ($MN)
60 Europe Haemoglobinopathies Market Analysis, by Alpha Thalassemia, (2013-2022) ($MN)
61 Europe Haemoglobinopathies Market Analysis, by Beta Thalassemia, (2013-2022) ($MN)
62 Europe Haemoglobinopathies Market Analysis, by Drug, (2013-2022) ($MN)
63 Europe Haemoglobinopathies Market Analysis, by NiCord, (2013-2022) ($MN)
64 Europe Haemoglobinopathies Market Analysis, by ZFP Transcription Factors, (2013-2022) ($MN)
65 Europe Haemoglobinopathies Market Analysis, by ALN-TMP, (2013-2022) ($MN)
66 Europe Haemoglobinopathies Market Analysis, by Drug Targeting PRMT5, (2013-2022) ($MN)
67 Europe Haemoglobinopathies Market Analysis, by Drug Targeting Protein Arginine Methyltransferase 5, (2013-2022) ($MN)
68 Europe Haemoglobinopathies Market Analysis, by Diagnosis, (2013-2022) ($MN)
69 Europe Haemoglobinopathies Market Analysis, by Genetic Testing, (2013-2022) ($MN)
70 Europe Haemoglobinopathies Market Analysis, by Blood Testing, (2013-2022) ($MN)
71 Europe Haemoglobinopathies Market Analysis, by Pre-implantation Genetic Diagnosis, (2013-2022) ($MN)
72 Europe Haemoglobinopathies Market Analysis, by Prenatal Genetic Testing, (2013-2022) ($MN)
73 Europe Haemoglobinopathies Market Analysis, by Haemoglobin Electrophoresis, (2013-2022) ($MN)
74 Europe Haemoglobinopathies Market Analysis, by Therapy, (2013-2022) ($MN)
75 Europe Haemoglobinopathies Market Analysis, by Iron Chelation Therapy, (2013-2022) ($MN)
76 Europe Haemoglobinopathies Market Analysis, by Blood Transfusion, (2013-2022) ($MN)
77 Europe Haemoglobinopathies Market Analysis, by Hydroxyurea, (2013-2022) ($MN)
78 Europe Haemoglobinopathies Market Analysis, by Bone Marrow Transplant, (2013-2022) ($MN)
79 Asia Pacific Haemoglobinopathies Market Analysis, by Country, (2013-2022) ($MN)
80 Asia Pacific Haemoglobinopathies Market Analysis, by Disorder, (2013-2022) ($MN)
81 Asia Pacific Haemoglobinopathies Market Analysis, by Sickle Cell Disease, (2013-2022) ($MN)
82 Asia Pacific Haemoglobinopathies Market Analysis, by Haemoglobin variants diseases, (2013-2022) ($MN)
83 Asia Pacific Haemoglobinopathies Market Analysis, by Haemoglobin C disease, (2013-2022) ($MN)
84 Asia Pacific Haemoglobinopathies Market Analysis, by Haemoglobin S-C disease, (2013-2022) ($MN)
85 Asia Pacific Haemoglobinopathies Market Analysis, by Thalassemia, (2013-2022) ($MN)
86 Asia Pacific Haemoglobinopathies Market Analysis, by Alpha Thalassemia, (2013-2022) ($MN)
87 Asia Pacific Haemoglobinopathies Market Analysis, by Beta Thalassemia, (2013-2022) ($MN)
88 Asia Pacific Haemoglobinopathies Market Analysis, by Drug, (2013-2022) ($MN)
89 Asia Pacific Haemoglobinopathies Market Analysis, by NiCord, (2013-2022) ($MN)
90 Asia Pacific Haemoglobinopathies Market Analysis, by ZFP Transcription Factors, (2013-2022) ($MN)
91 Asia Pacific Haemoglobinopathies Market Analysis, by ALN-TMP, (2013-2022) ($MN)
92 Asia Pacific Haemoglobinopathies Market Analysis, by Drug Targeting PRMT5, (2013-2022) ($MN)
93 Asia Pacific Haemoglobinopathies Market Analysis, by Drug Targeting Protein Arginine Methyltransferase 5, (2013-2022) ($MN)
94 Asia Pacific Haemoglobinopathies Market Analysis, by Diagnosis, (2013-2022) ($MN)
95 Asia Pacific Haemoglobinopathies Market Analysis, by Genetic Testing, (2013-2022) ($MN)
96 Asia Pacific Haemoglobinopathies Market Analysis, by Blood Testing, (2013-2022) ($MN)
97 Asia Pacific Haemoglobinopathies Market Analysis, by Pre-implantation Genetic Diagnosis, (2013-2022) ($MN)
98 Asia Pacific Haemoglobinopathies Market Analysis, by Prenatal Genetic Testing, (2013-2022) ($MN)
99 Asia Pacific Haemoglobinopathies Market Analysis, by Haemoglobin Electrophoresis, (2013-2022) ($MN)
100 Asia Pacific Haemoglobinopathies Market Analysis, by Therapy, (2013-2022) ($MN)
101 Asia Pacific Haemoglobinopathies Market Analysis, by Iron Chelation Therapy, (2013-2022) ($MN)
102 Asia Pacific Haemoglobinopathies Market Analysis, by Blood Transfusion, (2013-2022) ($MN)
103 Asia Pacific Haemoglobinopathies Market Analysis, by Hydroxyurea, (2013-2022) ($MN)
104 Asia Pacific Haemoglobinopathies Market Analysis, by Bone Marrow Transplant, (2013-2022) ($MN)
105 RoW Haemoglobinopathies Market Analysis, by Country, (2013-2022) ($MN)
106 RoW Haemoglobinopathies Market Analysis, by Disorder, (2013-2022) ($MN)
107 RoW Haemoglobinopathies Market Analysis, by Sickle Cell Disease, (2013-2022) ($MN)
108 RoW Haemoglobinopathies Market Analysis, by Haemoglobin variants diseases, (2013-2022) ($MN)
109 RoW Haemoglobinopathies Market Analysis, by Haemoglobin C disease, (2013-2022) ($MN)
110 RoW Haemoglobinopathies Market Analysis, by Haemoglobin S-C disease, (2013-2022) ($MN)
111 RoW Haemoglobinopathies Market Analysis, by Thalassemia, (2013-2022) ($MN)
112 RoW Haemoglobinopathies Market Analysis, by Alpha Thalassemia, (2013-2022) ($MN)
113 RoW Haemoglobinopathies Market Analysis, by Beta Thalassemia, (2013-2022) ($MN)
114 RoW Haemoglobinopathies Market Analysis, by Drug, (2013-2022) ($MN)
115 RoW Haemoglobinopathies Market Analysis, by NiCord, (2013-2022) ($MN)
116 RoW Haemoglobinopathies Market Analysis, by ZFP Transcription Factors, (2013-2022) ($MN)
117 RoW Haemoglobinopathies Market Analysis, by ALN-TMP, (2013-2022) ($MN)
118 RoW Haemoglobinopathies Market Analysis, by Drug Targeting PRMT5, (2013-2022) ($MN)
119 RoW Haemoglobinopathies Market Analysis, by Drug Targeting Protein Arginine Methyltransferase 5, (2013-2022) ($MN)
120 RoW Haemoglobinopathies Market Analysis, by Diagnosis, (2013-2022) ($MN)
121 RoW Haemoglobinopathies Market Analysis, by Genetic Testing, (2013-2022) ($MN)
122 RoW Haemoglobinopathies Market Analysis, by Blood Testing, (2013-2022) ($MN)
123 RoW Haemoglobinopathies Market Analysis, by Pre-implantation Genetic Diagnosis, (2013-2022) ($MN)
124 RoW Haemoglobinopathies Market Analysis, by Prenatal Genetic Testing, (2013-2022) ($MN)
125 RoW Haemoglobinopathies Market Analysis, by Haemoglobin Electrophoresis, (2013-2022) ($MN)
126 RoW Haemoglobinopathies Market Analysis, by Therapy, (2013-2022) ($MN)
127 RoW Haemoglobinopathies Market Analysis, by Iron Chelation Therapy, (2013-2022) ($MN)
128 RoW Haemoglobinopathies Market Analysis, by Blood Transfusion, (2013-2022) ($MN)
129 RoW Haemoglobinopathies Market Analysis, by Hydroxyurea, (2013-2022) ($MN)
130 RoW Haemoglobinopathies Market Analysis, by Bone Marrow Transplant, (2013-2022) ($MN)
1 Global Haemoglobinopathies Market Analysis, by Region, (2013-2022) ($MN)
2 Global Haemoglobinopathies Market Analysis, by Disorder, (2013-2022) ($MN)
3 Global Haemoglobinopathies Market Analysis, by Sickle Cell Disease, (2013-2022) ($MN)
4 Global Haemoglobinopathies Market Analysis, by Haemoglobin variants diseases, (2013-2022) ($MN)
5 Global Haemoglobinopathies Market Analysis, by Haemoglobin C disease, (2013-2022) ($MN)
6 Global Haemoglobinopathies Market Analysis, by Haemoglobin S-C disease, (2013-2022) ($MN)
7 Global Haemoglobinopathies Market Analysis, by Thalassemia, (2013-2022) ($MN)
8 Global Haemoglobinopathies Market Analysis, by Alpha Thalassemia, (2013-2022) ($MN)
9 Global Haemoglobinopathies Market Analysis, by Beta Thalassemia, (2013-2022) ($MN)
10 Global Haemoglobinopathies Market Analysis, by Drug, (2013-2022) ($MN)
11 Global Haemoglobinopathies Market Analysis, by NiCord, (2013-2022) ($MN)
12 Global Haemoglobinopathies Market Analysis, by ZFP Transcription Factors, (2013-2022) ($MN)
13 Global Haemoglobinopathies Market Analysis, by ALN-TMP, (2013-2022) ($MN)
14 Global Haemoglobinopathies Market Analysis, by Drug Targeting PRMT5, (2013-2022) ($MN)
15 Global Haemoglobinopathies Market Analysis, by Drug Targeting Protein Arginine Methyltransferase 5, (2013-2022) ($MN)
16 Global Haemoglobinopathies Market Analysis, by Diagnosis, (2013-2022) ($MN)
17 Global Haemoglobinopathies Market Analysis, by Genetic Testing, (2013-2022) ($MN)
18 Global Haemoglobinopathies Market Analysis, by Blood Testing, (2013-2022) ($MN)
19 Global Haemoglobinopathies Market Analysis, by Pre-implantation Genetic Diagnosis, (2013-2022) ($MN)
20 Global Haemoglobinopathies Market Analysis, by Prenatal Genetic Testing, (2013-2022) ($MN)
21 Global Haemoglobinopathies Market Analysis, by Haemoglobin Electrophoresis, (2013-2022) ($MN)
22 Global Haemoglobinopathies Market Analysis, by Therapy, (2013-2022) ($MN)
23 Global Haemoglobinopathies Market Analysis, by Iron Chelation Therapy, (2013-2022) ($MN)
24 Global Haemoglobinopathies Market Analysis, by Blood Transfusion, (2013-2022) ($MN)
25 Global Haemoglobinopathies Market Analysis, by Hydroxyurea, (2013-2022) ($MN)
26 Global Haemoglobinopathies Market Analysis, by Bone Marrow Transplant, (2013-2022) ($MN)
27 North America Haemoglobinopathies Market Analysis, by Country, (2013-2022) ($MN)
28 North America Haemoglobinopathies Market Analysis, by Disorder, (2013-2022) ($MN)
29 North America Haemoglobinopathies Market Analysis, by Sickle Cell Disease, (2013-2022) ($MN)
30 North America Haemoglobinopathies Market Analysis, by Haemoglobin variants diseases, (2013-2022) ($MN)
31 North America Haemoglobinopathies Market Analysis, by Haemoglobin C disease, (2013-2022) ($MN)
32 North America Haemoglobinopathies Market Analysis, by Haemoglobin S-C disease, (2013-2022) ($MN)
33 North America Haemoglobinopathies Market Analysis, by Thalassemia, (2013-2022) ($MN)
34 North America Haemoglobinopathies Market Analysis, by Alpha Thalassemia, (2013-2022) ($MN)
35 North America Haemoglobinopathies Market Analysis, by Beta Thalassemia, (2013-2022) ($MN)
36 North America Haemoglobinopathies Market Analysis, by Drug, (2013-2022) ($MN)
37 North America Haemoglobinopathies Market Analysis, by NiCord, (2013-2022) ($MN)
38 North America Haemoglobinopathies Market Analysis, by ZFP Transcription Factors, (2013-2022) ($MN)
39 North America Haemoglobinopathies Market Analysis, by ALN-TMP, (2013-2022) ($MN)
40 North America Haemoglobinopathies Market Analysis, by Drug Targeting PRMT5, (2013-2022) ($MN)
41 North America Haemoglobinopathies Market Analysis, by Drug Targeting Protein Arginine Methyltransferase 5, (2013-2022) ($MN)
42 North America Haemoglobinopathies Market Analysis, by Diagnosis, (2013-2022) ($MN)
43 North America Haemoglobinopathies Market Analysis, by Genetic Testing, (2013-2022) ($MN)
44 North America Haemoglobinopathies Market Analysis, by Blood Testing, (2013-2022) ($MN)
45 North America Haemoglobinopathies Market Analysis, by Pre-implantation Genetic Diagnosis, (2013-2022) ($MN)
46 North America Haemoglobinopathies Market Analysis, by Prenatal Genetic Testing, (2013-2022) ($MN)
47 North America Haemoglobinopathies Market Analysis, by Haemoglobin Electrophoresis, (2013-2022) ($MN)
48 North America Haemoglobinopathies Market Analysis, by Therapy, (2013-2022) ($MN)
49 North America Haemoglobinopathies Market Analysis, by Iron Chelation Therapy, (2013-2022) ($MN)
50 North America Haemoglobinopathies Market Analysis, by Blood Transfusion, (2013-2022) ($MN)
51 North America Haemoglobinopathies Market Analysis, by Hydroxyurea, (2013-2022) ($MN)
52 North America Haemoglobinopathies Market Analysis, by Bone Marrow Transplant, (2013-2022) ($MN)
53 Europe Haemoglobinopathies Market Analysis, by Country, (2013-2022) ($MN)
54 Europe Haemoglobinopathies Market Analysis, by Disorder, (2013-2022) ($MN)
55 Europe Haemoglobinopathies Market Analysis, by Sickle Cell Disease, (2013-2022) ($MN)
56 Europe Haemoglobinopathies Market Analysis, by Haemoglobin variants diseases, (2013-2022) ($MN)
57 Europe Haemoglobinopathies Market Analysis, by Haemoglobin C disease, (2013-2022) ($MN)
58 Europe Haemoglobinopathies Market Analysis, by Haemoglobin S-C disease, (2013-2022) ($MN)
59 Europe Haemoglobinopathies Market Analysis, by Thalassemia, (2013-2022) ($MN)
60 Europe Haemoglobinopathies Market Analysis, by Alpha Thalassemia, (2013-2022) ($MN)
61 Europe Haemoglobinopathies Market Analysis, by Beta Thalassemia, (2013-2022) ($MN)
62 Europe Haemoglobinopathies Market Analysis, by Drug, (2013-2022) ($MN)
63 Europe Haemoglobinopathies Market Analysis, by NiCord, (2013-2022) ($MN)
64 Europe Haemoglobinopathies Market Analysis, by ZFP Transcription Factors, (2013-2022) ($MN)
65 Europe Haemoglobinopathies Market Analysis, by ALN-TMP, (2013-2022) ($MN)
66 Europe Haemoglobinopathies Market Analysis, by Drug Targeting PRMT5, (2013-2022) ($MN)
67 Europe Haemoglobinopathies Market Analysis, by Drug Targeting Protein Arginine Methyltransferase 5, (2013-2022) ($MN)
68 Europe Haemoglobinopathies Market Analysis, by Diagnosis, (2013-2022) ($MN)
69 Europe Haemoglobinopathies Market Analysis, by Genetic Testing, (2013-2022) ($MN)
70 Europe Haemoglobinopathies Market Analysis, by Blood Testing, (2013-2022) ($MN)
71 Europe Haemoglobinopathies Market Analysis, by Pre-implantation Genetic Diagnosis, (2013-2022) ($MN)
72 Europe Haemoglobinopathies Market Analysis, by Prenatal Genetic Testing, (2013-2022) ($MN)
73 Europe Haemoglobinopathies Market Analysis, by Haemoglobin Electrophoresis, (2013-2022) ($MN)
74 Europe Haemoglobinopathies Market Analysis, by Therapy, (2013-2022) ($MN)
75 Europe Haemoglobinopathies Market Analysis, by Iron Chelation Therapy, (2013-2022) ($MN)
76 Europe Haemoglobinopathies Market Analysis, by Blood Transfusion, (2013-2022) ($MN)
77 Europe Haemoglobinopathies Market Analysis, by Hydroxyurea, (2013-2022) ($MN)
78 Europe Haemoglobinopathies Market Analysis, by Bone Marrow Transplant, (2013-2022) ($MN)
79 Asia Pacific Haemoglobinopathies Market Analysis, by Country, (2013-2022) ($MN)
80 Asia Pacific Haemoglobinopathies Market Analysis, by Disorder, (2013-2022) ($MN)
81 Asia Pacific Haemoglobinopathies Market Analysis, by Sickle Cell Disease, (2013-2022) ($MN)
82 Asia Pacific Haemoglobinopathies Market Analysis, by Haemoglobin variants diseases, (2013-2022) ($MN)
83 Asia Pacific Haemoglobinopathies Market Analysis, by Haemoglobin C disease, (2013-2022) ($MN)
84 Asia Pacific Haemoglobinopathies Market Analysis, by Haemoglobin S-C disease, (2013-2022) ($MN)
85 Asia Pacific Haemoglobinopathies Market Analysis, by Thalassemia, (2013-2022) ($MN)
86 Asia Pacific Haemoglobinopathies Market Analysis, by Alpha Thalassemia, (2013-2022) ($MN)
87 Asia Pacific Haemoglobinopathies Market Analysis, by Beta Thalassemia, (2013-2022) ($MN)
88 Asia Pacific Haemoglobinopathies Market Analysis, by Drug, (2013-2022) ($MN)
89 Asia Pacific Haemoglobinopathies Market Analysis, by NiCord, (2013-2022) ($MN)
90 Asia Pacific Haemoglobinopathies Market Analysis, by ZFP Transcription Factors, (2013-2022) ($MN)
91 Asia Pacific Haemoglobinopathies Market Analysis, by ALN-TMP, (2013-2022) ($MN)
92 Asia Pacific Haemoglobinopathies Market Analysis, by Drug Targeting PRMT5, (2013-2022) ($MN)
93 Asia Pacific Haemoglobinopathies Market Analysis, by Drug Targeting Protein Arginine Methyltransferase 5, (2013-2022) ($MN)
94 Asia Pacific Haemoglobinopathies Market Analysis, by Diagnosis, (2013-2022) ($MN)
95 Asia Pacific Haemoglobinopathies Market Analysis, by Genetic Testing, (2013-2022) ($MN)
96 Asia Pacific Haemoglobinopathies Market Analysis, by Blood Testing, (2013-2022) ($MN)
97 Asia Pacific Haemoglobinopathies Market Analysis, by Pre-implantation Genetic Diagnosis, (2013-2022) ($MN)
98 Asia Pacific Haemoglobinopathies Market Analysis, by Prenatal Genetic Testing, (2013-2022) ($MN)
99 Asia Pacific Haemoglobinopathies Market Analysis, by Haemoglobin Electrophoresis, (2013-2022) ($MN)
100 Asia Pacific Haemoglobinopathies Market Analysis, by Therapy, (2013-2022) ($MN)
101 Asia Pacific Haemoglobinopathies Market Analysis, by Iron Chelation Therapy, (2013-2022) ($MN)
102 Asia Pacific Haemoglobinopathies Market Analysis, by Blood Transfusion, (2013-2022) ($MN)
103 Asia Pacific Haemoglobinopathies Market Analysis, by Hydroxyurea, (2013-2022) ($MN)
104 Asia Pacific Haemoglobinopathies Market Analysis, by Bone Marrow Transplant, (2013-2022) ($MN)
105 RoW Haemoglobinopathies Market Analysis, by Country, (2013-2022) ($MN)
106 RoW Haemoglobinopathies Market Analysis, by Disorder, (2013-2022) ($MN)
107 RoW Haemoglobinopathies Market Analysis, by Sickle Cell Disease, (2013-2022) ($MN)
108 RoW Haemoglobinopathies Market Analysis, by Haemoglobin variants diseases, (2013-2022) ($MN)
109 RoW Haemoglobinopathies Market Analysis, by Haemoglobin C disease, (2013-2022) ($MN)
110 RoW Haemoglobinopathies Market Analysis, by Haemoglobin S-C disease, (2013-2022) ($MN)
111 RoW Haemoglobinopathies Market Analysis, by Thalassemia, (2013-2022) ($MN)
112 RoW Haemoglobinopathies Market Analysis, by Alpha Thalassemia, (2013-2022) ($MN)
113 RoW Haemoglobinopathies Market Analysis, by Beta Thalassemia, (2013-2022) ($MN)
114 RoW Haemoglobinopathies Market Analysis, by Drug, (2013-2022) ($MN)
115 RoW Haemoglobinopathies Market Analysis, by NiCord, (2013-2022) ($MN)
116 RoW Haemoglobinopathies Market Analysis, by ZFP Transcription Factors, (2013-2022) ($MN)
117 RoW Haemoglobinopathies Market Analysis, by ALN-TMP, (2013-2022) ($MN)
118 RoW Haemoglobinopathies Market Analysis, by Drug Targeting PRMT5, (2013-2022) ($MN)
119 RoW Haemoglobinopathies Market Analysis, by Drug Targeting Protein Arginine Methyltransferase 5, (2013-2022) ($MN)
120 RoW Haemoglobinopathies Market Analysis, by Diagnosis, (2013-2022) ($MN)
121 RoW Haemoglobinopathies Market Analysis, by Genetic Testing, (2013-2022) ($MN)
122 RoW Haemoglobinopathies Market Analysis, by Blood Testing, (2013-2022) ($MN)
123 RoW Haemoglobinopathies Market Analysis, by Pre-implantation Genetic Diagnosis, (2013-2022) ($MN)
124 RoW Haemoglobinopathies Market Analysis, by Prenatal Genetic Testing, (2013-2022) ($MN)
125 RoW Haemoglobinopathies Market Analysis, by Haemoglobin Electrophoresis, (2013-2022) ($MN)
126 RoW Haemoglobinopathies Market Analysis, by Therapy, (2013-2022) ($MN)
127 RoW Haemoglobinopathies Market Analysis, by Iron Chelation Therapy, (2013-2022) ($MN)
128 RoW Haemoglobinopathies Market Analysis, by Blood Transfusion, (2013-2022) ($MN)
129 RoW Haemoglobinopathies Market Analysis, by Hydroxyurea, (2013-2022) ($MN)
130 RoW Haemoglobinopathies Market Analysis, by Bone Marrow Transplant, (2013-2022) ($MN)
